Welcome to our dedicated page for Quantum-Si news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si stock.
Quantum-Si Incorporated develops proteomics technology for single-molecule protein sequencing and protein analysis. Its updates center on benchtop platform development, real-time kinetic-based detection, and product work around Proteus instruments, the KinetIQ Array and Platinum Pro customer use.
Recurring company news includes quarterly financial results and non-GAAP operating measures, Proteus prototype and integrated-instrument sequencing milestones, amino-acid detection coverage, customer sample testing, scientific posters and manuscripts using Quantum-Si technology, investor conference participation, and equity-inducement grants under Nasdaq rules.
Quantum-Si (Nasdaq: QSI) completed sequencing of multiple customer samples on a Proteus prototype, testing samples on both Platinum Pro and the Proteus prototype.
According to the company, the Proteus prototype with a developmental sequencing kit delivered improved amino acid coverage, longer read lengths, more peptides identified and greater sequencing output versus Platinum Pro.
Quantum-Si (NASDAQ: QSI) announced a multi-city roadshow to build awareness for its Proteus protein sequencing platform and develop a customer funnel ahead of commercial launch.
First events are in Seattle on April 7, 2026, Washington, D.C. on April 30, 2026, and Houston on May 5, 2026; additional U.S. and European dates will follow.
Quantum-Si (Nasdaq: QSI) granted 88,781 restricted stock units (RSUs) to new employees under its 2023 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on March 20, 2027, with the remainder vesting in 12 equal quarterly installments, subject to continued employment and plan terms.
Quantum-Si (Nasdaq: QSI) reported fourth quarter 2025 revenue of $0.5M and full-year 2025 revenue of $2.4M, with gross margins of 27% (Q4) and 47% (full year).
The company announced a Proteus list price of $425,000, reiterated a year-end 2026 launch target, and provided 2026 guidance: revenue ~$1.0M, adjusted operating expenses ≤$98.0M, and total cash usage ≤$93.0M. Cash and investments totaled $215.8M as of December 31, 2025.
Quantum-Si (Nasdaq: QSI) announced that its Compensation Committee granted 52,296 restricted stock units (RSUs) to new employees under the company’s 2023 Inducement Equity Incentive Plan.
The RSUs vest 25% on March 20, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment and plan terms.
Quantum-Si (Nasdaq: QSI) will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026. Management will host a conference call and live webcast at 4:30 PM ET the same day to discuss results and provide a business update.
Webcast access and dial-in registration details are available on the company’s Investors section; an archived replay will be posted after the event.
Quantum-Si (NASDAQ: QSI) announced two new manuscripts showing single-molecule protein sequencing applied to clinical proteomics and pathogen/toxin detection. One paper on hemoglobin variants was peer reviewed and published in Journal of Analytical Chemistry; a U.S. Naval Research Laboratory preprint reports a workflow delivering biological sample-to-result in under 24 hours.
The studies demonstrate direct identification of difficult hemoglobin variants, detection of long single-domain antibodies and toxoids from complex matrices, and highlight the company’s benchtop Proteus strategy.
Quantum-Si (Nasdaq: QSI) launched a Version 3 Library Preparation Kit and a suite of data analysis enhancements on December 22, 2025. The Version 3 kit requires 200 ng or less total protein input, a 100-fold improvement versus the prior kit, and internal validation shows detection of proteins with as little as 1–2 ng input (under 1% relative abundance in mixtures). The analysis updates add detection of methionine, improve peptide alignment and protein inference, and expand amino acid coverage to 15 amino acids. Combined with the Version 4 Sequencing Kit launched September 2025, the company says users should see improved analysis of scarce samples and low‑abundance biomarkers.
Quantum-Si (Nasdaq: QSI) announced that its Compensation Committee granted 39,920 restricted stock units (RSUs) to new employees under the 2023 Inducement Equity Incentive Plan. The grants were made as inducements pursuant to Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on December 20, 2026, with the remaining 75% vesting in 12 equal quarterly installments thereafter, subject to continued employment and the RSU agreement and plan terms.
Quantum-Si (Nasdaq: QSI) summarized progress from its Investor & Analyst Day on November 19, 2025, outlining development milestones and timelines for the Proteus platform.
Key points: Proteus is on track for an end‑of‑2026 launch with an Early Access Program expected in summer 2026, planned coverage of 18 amino acids at launch, and product pricing to be announced in Q2 2026. An accelerated program aims to demonstrate detection of all 20 amino acids in 2026 with commercial capability on Proteus in 2027. The company unveiled a new controlled cleavage sequencing chemistry it says can enable billions of sequencing reads when combined with Proteus, and noted a suite of PTM methods for broad post‑translational modification analysis.